This content is from: Portfolio How Face-to-Face Meetings Pay Off Research suggests investors can identify mispricings through in-person meetings with corporate leaders, with more meetings linked to higher stock returns. By Amy Whyte February 05, 2021
This content is from: Premium Perceptive’s China Rx The life sciences giant is one of at least seven hedge funds that have invested in LianBio, scheduled to go public this week. Here’s why this IPO is different. By Stephen Taub October 25, 2021
This content is from: Research It’s Been One Year Since Covid-19 Arrived in China. These Are the Research Firms That Got Investors Through It. China International Capital Corp. and Huatai Securities lead the 2020 All-China Research Team. By Alexandra DeLuca December 09, 2020
This content is from: Portfolio China's Sovereign Wealth Fund Exits Investment in Blackstone China Investment Corp. no longer holds any of the units it purchased in the private equity firm in June 2007. By Christine Idzelis March 14, 2018
This content is from: Research CICC’s Reign Continues in Chinese Equity Sales China International Capital Corp. stayed on top of II’s All-China Sales Team in a “volatile and eventful” year for Chinese equities. By Alexandra DeLuca November 06, 2019
This content is from: Corner Office China Investment Corp. Chairman May Be Stepping Down to Rise Higher Ding Xuedong’s resignation from the Chinese sovereign wealth fund may signal a promotion, taking him closer to President Xi Jinping’s inner circle. By Allen T. Cheng February 24, 2017
